^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PNT2002

    i
    Other names: PNT2002, 177Lu-PSMA radiotherapeutic, 177Lu-PSMA-I&T, 177Lu-PNT2002
    Company:
    Eli Lilly, Lantheus
    Drug class:
    Ionizing radiation emitter, PSMA inhibitor
    Related drugs:
    22d
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P1/2 trial • Metastases
    |
    Keytruda (pembrolizumab) • PNT2002
    23d
    177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (clinicaltrials.gov)
    P2, N=93, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PNT2002
    1m
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    PNT2002
    9ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2; N=33 --> 48
    Enrollment change • Metastases
    |
    CELLSEARCH®
    |
    PNT2002 • rosopatamab-225Ac (CONV01-α)
    9ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2; Recruiting --> Suspended
    Trial suspension • Metastases
    |
    CELLSEARCH®
    |
    PNT2002 • rosopatamab-225Ac (CONV01-α)
    over2years
    225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC (clinicaltrials.gov)
    P1/2; N=33; Recruiting; Sponsor: Weill Medical College of Cornell University; Not yet recruiting --> Recruiting
    Enrollment open
    |
    CELLSEARCH®
    |
    PNT2002 • rosopatamab-225Ac (CONV01-α)
    almost3years
    225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC (clinicaltrials.gov)
    P1/2; N=33; Not yet recruiting; Sponsor:Weill Medical College of Cornell University
    New P1/2 trial
    |
    CELLSEARCH®
    |
    PNT2002 • rosopatamab-225Ac (CONV01-α)